Abstract
Dramatic disruptions in technologies can result in the creation of new markets, the emergence of new paradigms, and the displacement of entrenched approaches and business models. This can be especially pronounced when multiple technologies converge to create something new. Today, artificial intelligence (“AI”) is acting as an accelerant for such technology transformations. Still, the scope and depth of its impact will depend in part on our ability to address challenging problems that are surfacing without solutions. Industries will pursue AI for their corporate missions and to create shareholder value. But the timescales and applications can be incongruent with important public needs and with the longer research horizons required to make real progress. Public-Private partnerships are an important mechanism for tackling these rapidly emerging new, complex, challenging problems. This paper examines our experience gained by creating a unique public-private partnership to apply AI to one example of a hard problem that is particularly timely today— dramatically accelerating drug discovery.
| Original language | English |
|---|---|
| Pages (from-to) | 42-49 |
| Number of pages | 8 |
| Journal | Journal of Commercial Biotechnology |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 11 2020 |
Funding
This work has been in part co-authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The content is solely the responsibility of the authors and does not necessarily represent the ocial views of the UT-Battelle, or the Department of Energy. We would like to acknowledge Atom Project, Lawrence Livermore National Laboratory (LLNL), and Oak Ridge National Laboratory (ORNL).